# Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

> **NCT05263583** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cothera Bioscience, Inc** · enrollment: 14 (actual)

## Conditions studied

- High-grade B-cell Lymphoma
- Burkitt Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphatic Diseases
- Lymphoma, High-Grade
- C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
- C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
- C-Myc Gene Rearrangement

## Interventions

- **DRUG:** Sepantronium Bromide

## Key facts

- **NCT ID:** NCT05263583
- **Lead sponsor:** Cothera Bioscience, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-09
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-06-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263583, "Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05263583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*